Imvanex

Modified Vaccinia Ankara (MVA) live virus, the active ingredient in Imvanex, is a live viral vaccine presented as an unspecified strength/solution for subcutaneous injection use. It induces immunity to prevent smallpox, monkeypox and other orthopoxvirus infections in adults and children as indicated. The vaccine is administered as a single subcutaneous dose and is authorized for use throughout the European Union.

GNH USA supplies Imvanex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance across multiple markets.

Imvanex, a live viral vaccine targeting orthopoxviruses, is indicated for the following preventive uses:

Smallpox: Provides active immunity to prevent smallpox infection in individuals at risk. Monkeypox: Confers protection against monkeypox virus exposure in endemic or outbreak settings. Other orthopoxvirus infections: Offers cross‑protective immunity against related orthopoxviruses such as vaccinia and cowpox. Post‑exposure prophylaxis: Can be used shortly after exposure to orthopoxviruses to reduce disease severity.

Imvanex may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild to moderate pain at the injection site lasting 1‑2 days. - Redness: localized erythema around the injection area that resolves spontaneously. - Swelling: temporary swelling at the site, usually subsiding within a few days. - Fever: low‑grade fever (≤38.5 °C) occurring within 24‑48 hours after vaccination. - Headache: mild headache reported by some recipients during the first 24 hours. - Fatigue: general tiredness that may last up to 48 hours.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with hives, airway swelling, requiring immediate emergency treatment. - Myocarditis: inflammation of the heart muscle, reported rarely, presenting with chest pain or shortness of breath. - Encephalitis: inflammation of the brain, a rare neurologic event that may cause seizures or altered consciousness. - Disseminated vaccinia infection: uncontrolled spread of vaccinia virus in immunocompromised individuals, leading to widespread lesions. - Severe skin reactions: such as eczema vaccinatum or generalized rash, occurring in patients with pre‑existing skin conditions.

Prior to administering Imvanex, healthcare professionals should observe the following precautions to ensure safety. - Assess immune status: verify the patient is not severely immunocompromised. - Contraindicate in severe eczema: avoid use in individuals with active eczema or atopic dermatitis. - Defer during acute illness: postpone vaccination if the patient has a febrile or severe infection. - Monitor cardiac symptoms: observe for chest pain or palpitations after vaccination. - Avoid concomitant live vaccines: do not co‑administer other live viral vaccines within four weeks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imvanex can interact with certain medicines or vaccines; awareness of these interactions helps prevent reduced efficacy or increased risk.

Major Interactions (Avoid): - High‑dose corticosteroids: suppress immune response, diminishing vaccine effectiveness. - Chemotherapy agents: profound immunosuppression may lead to uncontrolled viral replication. - Biologic immunomodulators (e.g., TNF‑α inhibitors): increase risk of adverse vaccine reactions. - HIV with CD4 <200 cells/µL: severe immunodeficiency contraindicates use. - Other live vaccines: simultaneous administration can cause interference or enhanced reactogenicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: may increase risk of bleeding at the injection site. - Antipyretics (e.g., acetaminophen) taken prophylactically: could blunt antibody response if used before vaccination. - Immunoglobulin therapy: may neutralize vaccine virus if given shortly before or after vaccination.